VJHemOnc is committed to improving our service to you

ISA 2020 | RNAi therapeutics for ATTR amyloidosis

VJHemOnc is committed to improving our service to you

Mathew Maurer

Mathew Maurer, MD, Columbia University, New York, NY, discusses the use of RNAi therapeutics for ATTR amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter